Database : MEDLINE
Search on : head [Words]
References found : 349463 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 34947 go to page                         

  1 / 349463 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 25769142
[Au] Autor:Matzuka B; Mehlsen J; Tran H; Olufsen MS
[Ti] Title:Using Kalman Filtering to Predict Time-Varying Parameters in a Model Predicting Baroreflex Regulation During Head-Up Tilt.
[So] Source:IEEE Trans Biomed Eng;62(8):1992-2000, 2015 Aug.
[Is] ISSN:1558-2531
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:The cardiovascular control system is continuously engaged to maintain homeostasis, but it is known to fail in a large cohort of patients suffering from orthostatic intolerance. Numerous clinical studies have been put forward to understand how the system fails, yet noninvasive clinical data are sparse, typical studies only include measurements of heart rate and blood pressure, as a result it is difficult to determine what mechanisms that are impaired. It is known, that blood pressure regulation is mediated by changes in heart rate, vascular resistance, cardiac contractility, and a number of other factors. Given that numerous factors contribute to changing these quantities, it is difficult to devise a physiological model describing how they change in time. One way is to build a model that allows these controlled quantities to change and to compare dynamics between subject groups. To do so, it requires more knowledge of how these quantities change for healthy subjects. This study compares two methods predicting time-varying changes in cardiac contractility and vascular resistance during head-up tilt. Similar to the study by Williams etal. [51], the first method uses piecewise linear splines, while the second uses the ensemble transform Kalman filter (ETKF) [1], [11], [12], [33]. In addition, we show that the delayed rejection adaptive Metropolis (DRAM) algorithm can be used for predicting parameter uncertainties within the spline methodology, which is compared with the variability obtained with the ETKF. While the spline method is easier to set up, this study shows that the ETKF has a significantly shorter computational time. Moreover, while uncertainty of predictions can be augmented to spline predictions using DRAM, these are readily available with the ETKF.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1507
[Cu] Class update date: 150718
[Lr] Last revision date:150718
[Js] Journal subset:IM
[St] Status:In-Data-Review
[do] DOI:10.1109/TBME.2015.2409211

  2 / 349463 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 26021283
[Au] Autor:Cruickshanks KJ; Dhar S; Dinces E; Fifer RC; Gonzalez F; Heiss G; Hoffman HJ; Lee DJ; Newhoff M; Tocci L; Torre P; Tweed TS
[Ad] Address:Department of Ophthalmology and Visual Sciences, University of Wisconsin School of Medicine and Public Health, Madison2Department of Population Health Sciences, University of Wisconsin School of Medicine and Public Health, Madison....
[Ti] Title:Hearing Impairment Prevalence and Associated Risk Factors in the Hispanic Community Health Study/Study of Latinos.
[So] Source:JAMA Otolaryngol Head Neck Surg;141(7):641-8, 2015 Jul 1.
[Is] ISSN:2168-619X
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:IMPORTANCE: Hearing impairment is common in adults, but few studies have addressed it in the US Hispanic/Latino population. OBJECTIVE: To determine the prevalence of hearing impairment among US Hispanic/Latino adults of diverse backgrounds and determine associations with potential risk factors. DESIGN, SETTING, AND PARTICIPANTS: The Hispanic Community Health Study/Study of Latinos (HCHS/SOL) is a population-based sample of Hispanics/Latinos in four US communities (Bronx, New York; Chicago, Illinois; Miami, Florida; and San Diego, California). Examinations were conducted from 2008 through 2011. The HCHS/SOL examined 16 415 self-identified Hispanic/Latino persons aged 18 to 74 years recruited from randomly selected households using a stratified 2-stage area probability sample design based on census block groups and households within block groups. MAIN OUTCOMES AND MEASURES: Hearing thresholds were measured by pure-tone audiometry. Hearing impairment was defined as a pure-tone average (PTA) of thresholds at 0.5, 1, 2, and 4 kHz greater than 25 dB hearing level. Bilateral hearing impairment required a PTA greater than 25 dB hearing level in both ears. Multivariable analyses included adjustments for sociodemographic and lifestyle variables, body mass index, and medical conditions. RESULTS: The prevalence of hearing impairment was 15.06% (SE, 0.44%) overall, and 8.24% (SE, 0.33%) had bilateral hearing impairment. The prevalence of hearing impairment was higher among people 45 years and older, ranging by Hispanic/Latino background from 29.35% to 41.20% among men and 17.89% to 32.11% among women. The multivariable-adjusted odds of hearing impairment was greater for participants of Puerto Rican background compared with Mexican background (odds ratio [OR], 1.57 [95% CI, 1.10-2.25]). The odds of hearing impairment were lower with more education (OR, 0.71 [95% CI, 0.59-0.86] for at least high school) and higher income (OR, 0.58 [95% CI, 0.36-0.92] for >$75 000 vs ≤$10 000). Noise exposure (OR, 1.35 [95% CI, 1.07-1.70]), diabetes (OR, 1.57 [95% CI, 1.27-1.94]), and prediabetes (OR, 1.37 [95% CI, 1.12-1.67]) were associated with hearing impairment. CONCLUSIONS AND RELEVANCE: Hearing impairment is a common problem for older Hispanics/Latinos in these communities and is associated with socioeconomic factors, noise exposure, and abnormal glucose metabolism. Longitudinal studies are needed to determine whether these factors are involved in the etiology of hearing impairment and to identify ways to prevent or delay age-related changes in hearing.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1507
[Cu] Class update date: 150718
[Lr] Last revision date:150718
[Js] Journal subset:AIM; IM
[St] Status:In-Data-Review
[do] DOI:10.1001/jamaoto.2015.0889

  3 / 349463 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
PubMed Central Full text
Full text

[PMID]: 25582648
[Au] Autor:Deleanu B; Prejbeanu R; Crisan D; Vermesan D; Predescu V; Tsiridis E
[Ad] Address:1st Orthopedics and Traumatology Clinic, Emergency Clinical County Hospital Timisoara, 10 I. Bulbuca Blvd, 300737, Timisoara, Romania. deleanubogdan@yahoo.com....
[Ti] Title:Combined bilateral femoral head necrosis and pertrochanteric fracture: a case report.
[So] Source:J Med Case Rep;9(1):25, 2015.
[Is] ISSN:1752-1947
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:INTRODUCTION: Modular femoral implants have become a regular feature of revision hip surgery. However, for a primary hip arthroplasty, such as a femoral neck fracture case, the implant of choice is a standard femoral component, while compelling literature evidence have made osteosynthesis the standard procedure for the vast majority of trochanteric fractures. CASE PRESENTATION: We present the case of a 66-year-old Caucasian woman presenting with two trochanteric fractures associated with primary and secondary hip osteoarthritis that were treated with an uncemented total hip replacement with a modular femoral component. CONCLUSIONS: We found that a modular femoral component can address the issues of stability and, in our case, proved to be a viable solution for treating cases that are complicated by concomitant acetabular or femoral head and neck pathology.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1507
[Cu] Class update date: 150718
[Lr] Last revision date:150718
[Js] Journal subset:IM
[St] Status:In-Data-Review
[do] DOI:10.1186/1752-1947-9-25

  4 / 349463 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 25239912
[Au] Autor:Stadig SM; Bergh AK
[Ad] Address:SLU, Department of Animal Health and Welfare, Skara, Sweden sarah.stadig@slu.se.
[Ti] Title:Gait and jump analysis in healthy cats using a pressure mat system.
[So] Source:J Feline Med Surg;17(6):523-9, 2015 Jun.
[Is] ISSN:1532-2750
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Physical orthopaedic examination in cats does not always reveal signs of lameness and no objective gait analysis method has yet been standardised for use in cats. The aims of the present study were to define appropriate parameters for pressure mat analyses during walk and jump, and to define reference values for gait parameters of healthy cats. Further, the distribution of the vertical force within the paws and the influence of a non-centred head position were investigated. The hypothesis was that cats have a symmetrical gait, a front/hindlimb asymmetry similar to dogs, and that peak vertical force (PVF) and vertical impulse (VI) have high intraclass correlation coefficients, confirming the reliability of these parameters. Data for walking (n = 46) showed gait symmetry indices of close to 1.0, besides PVF front/hind (1.3 0.2). The PVF front/hind for jumping cats (n = 16) was 1.7 0.6. Results from the distribution of the vertical force within the paw (n = 39) showed that the main weight during a strike is transferred from the caudal towards the craniomedial part of the paw. The findings support the hypothesis that healthy cats have similar gait symmetry to healthy dogs and that PVF and VI are reliable gait parameters. In conclusion, the present study provides a reference interval for healthy cats. Further studies are needed to investigate gait parameters in cats with orthopaedic disease.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1505
[Js] Journal subset:IM
[St] Status:In-Process
[do] DOI:10.1177/1098612X14551588

  5 / 349463 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 25193279
[Au] Autor:Melville K; Smith KC; Dobromylskyj MJ
[Ad] Address:Pathology and Pathogen Biology, Royal Veterinary College, Hatfield, UK.
[Ti] Title:Feline cutaneous mast cell tumours: a UK-based study comparing signalment and histological features with long-term outcomes.
[So] Source:J Feline Med Surg;17(6):486-93, 2015 Jun.
[Is] ISSN:1532-2750
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Feline cutaneous mast cell tumours (MCTs) are the second most common skin tumour in cats; but, unlike in dogs, there is currently no histological grading system for this type of tumour. This study recorded the signalment and anatomical location from a total of 287 records from MCTs submitted to a UK commercial diagnostic laboratory. Questionnaires to submitting practices were used to obtain follow-up data, and the histological features of 86 tumours were evaluated from 69 cats with a known outcome. Twelve of the 69 cats (17.4%) died of MCTs, with significantly lower survival times. The median age of cats presenting with MCTs was 11 years (range 5 months-19 years), with no sex or neutered status predilection. Some pedigree breeds were more susceptible to MCTs, particularly the Siamese, Burmese, Russian Blue and Ragdoll. The head was the most common site in younger cats, compared with the trunk in older cats. The number of tumours had no effect on survival. A new subcategory of well-differentiated MCTs with prominent multinucleated cells is described, and three of the five cats with this novel form died from MCT-related disease. There was an association between mitotic index and survival time. However, there was no significant association between histological type and survival.
[Pt] Publication type:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Entry month:1505
[Js] Journal subset:IM
[St] Status:In-Process
[do] DOI:10.1177/1098612X14548784

  6 / 349463 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 24985969
[Au] Autor:Newton JA; de Vicente F; Haugland SP; Scase TJ; Helm J
[Ad] Address:School of Veterinary Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK....
[Ti] Title:Extra-nodal subcutaneous Hodgkin's-like lymphoma and subsequent regression in a cat.
[So] Source:J Feline Med Surg;17(6):543-7, 2015 Jun.
[Is] ISSN:1532-2750
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Hodgkin's-like lymphoma is a slow growing neoplasm, usually affecting the lymph nodes of the head and neck, which has been sporadically described in veterinary patients. This report describes the clinical and histopathological features in a 9-year-old male neutered Siamese cat that presented with a 6 week history of mid-dorsocranial swelling. Immunohistochemistry demonstrated positive staining for CD79a, paired box protein and B lymphocyte antigen-36, with variable, weak-to-moderate cytoplasmic staining for human leukocyte antigen-DR and CD18, and negative staining for antimacrophage antibody. The diagnosis based on incisional biopsy was Hodgkin's-like lymphoma; however, no evidence of neoplasia was found following wide surgical excision. This case report demonstrates two unreported items of note: the novel extranodal site of Hodgkin's-like lymphoma in a cat and tumour regression following initial biopsy. It is hypothesised that the surgical trauma of biopsying the lesion or the introduction of foreign material may have caused the regression of the neoplastic cells through induction of an anti-tumour immune or inflammatory response.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1505
[Js] Journal subset:IM
[St] Status:In-Process
[do] DOI:10.1177/1098612X14541262

  7 / 349463 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 25875782
[Au] Autor:Zhang L; Sun J; Wang B; Ren JC; Su W; Zhang T
[Ad] Address:Department of Orthopedics, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, China.
[Ti] Title:MicroRNA-10b Triggers the Epithelial-Mesenchymal Transition (EMT) of Laryngeal Carcinoma Hep-2 Cells by Directly Targeting the E-cadherin.
[So] Source:Appl Biochem Biotechnol;176(1):33-44, 2015 May.
[Is] ISSN:1559-0291
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Laryngeal carcinoma is the second most common malignancy of the head and neck squamous cell carcinoma.Therefore, there is an urgent need to understand the molecular mechanism of its metastasis. The present study was designed to investigate effects of miR-10b on the invasion and migration of laryngeal Hep-2 cells. We found that miR-10b had limited effects on cell proliferation; however, it can significantly promote the migration and invasion of Hep-2 cells. Further studies revealed that overexpression of miR-10b can induce the epithelial-mesenchymal transition (EMT) of Hep-2 cells by acquiring mesenchymal spindle-like morphology and increasing the expression of N-cadherin (N-Cad) with a concomitant decrease of E-cadherin (E-Cad). However, the messenger RNA (mRNA) and protein level of transcription factors such as Snail, Slug, Twist and ZEB was not changed during this process. Bioinformatic analysis revealed that miR-10b can directly target CDH1 (E-Cad gene) at nucleotides 461 and 481 within the 3'-UTR. This was confirmed by the results that miR-10 downregulated the protein and mRNA levels of E-Cad via a time-dependent manner and luciferase analysis by use of four-nucleotide substitution in the core binding sites. The present study provided a better understanding of laryngeal carcinoma metastasis and the roles of miR-10b during this process.
[Pt] Publication type:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Entry month:1505
[Js] Journal subset:IM
[St] Status:In-Process
[do] DOI:10.1007/s12010-015-1505-6

  8 / 349463 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
PubMed Central Full text
Full text

[PMID]: 25971349
[Au] Autor:Davis MA; Higgins J; Li Z; Gilbert-Diamond D; Baker ER; Das A; Karagas MR
[Ad] Address:Children's Environmental Health and Disease Prevention Research Center at Dartmouth, Hanover, NH, USA. mattadav@umich.edu....
[Ti] Title:Preliminary analysis of in utero low-level arsenic exposure and fetal growth using biometric measurements extracted from fetal ultrasound reports.
[So] Source:Environ Health;14:12, 2015.
[Is] ISSN:1476-069X
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:BACKGROUND: Early life exposure to arsenic is associated with decreased birth weight in highly exposed populations but little is known about effects of low-level arsenic exposure on growth in utero. METHODS: Using a sample of 272 pregnancies from New Hampshire we obtained biometric measurements directly from fetal ultrasound reports commonly found in electronic medical records. We used information extraction methods to develop and validate an automated approach for mining biometric measurements from the text of clinical reports. As a preliminary analysis, we examined associations between in utero low-level arsenic exposure (as measured by maternal urinary arsenic concentration) and fetal growth measures (converted to Z-scores based on reference populations for estimated fetal weight, head, and other body measures) at approximately 18 weeks of gestation. RESULTS: In a preliminary cross-sectional analysis of 223 out of 272 pregnancies, maternal urinary arsenic concentration (excluding arsenobetaine) was associated with a reduction in head circumference Z-score (Spearman correlation coefficient, rs = -0.08, p-value = 0.21) and a stronger association was observed among female fetuses at approximately 18 weeks of gestation (rs = - 0.21, p-value < 0.05). Although, associations were attenuated in adjusted analyses - among female fetuses a 1 g/L increase in maternal urinary arsenic concentration was associated with a decrease of 0.047 (95% CI: -0.115, 0.021) in head circumference and 0.072 (95% CI: -0.151, 0.007) decrease in biparietal head diameter Z-score. CONCLUSIONS: Our study demonstrates that useful data can be extracted directly from electronic medical records for epidemiologic research. We also found evidence that exposure to low-level arsenic may be associated with reduced head circumference in a sex dependent manner that warrants further investigation.
[Pt] Publication type:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.
[Em] Entry month:1505
[Cu] Class update date: 150718
[Lr] Last revision date:150718
[Js] Journal subset:IM
[St] Status:In-Process
[do] DOI:10.1186/1476-069X-14-12

  9 / 349463 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 25873175
[Au] Autor:Elkabets M; Pazarentzos E; Juric D; Sheng Q; Pelossof RA; Brook S; Benzaken AO; Rodon J; Morse N; Yan JJ; Liu M; Das R; Chen Y; Tam A; Wang H; Liang J; Gurski JM; Kerr DA; Rosell R; Teixid C; Huang A; Ghossein RA; Rosen N; Bivona TG; Scaltriti M; Baselga J
[Ad] Address:Human Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New York, NY10065, USA....
[Ti] Title:AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.
[So] Source:Cancer Cell;27(4):533-46, 2015 Apr 13.
[Is] ISSN:1878-3686
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Phosphoinositide-3-kinase (PI3K)-α inhibitors have shown clinical activity in squamous cell carcinomas (SCCs) of head and neck (H&N) bearing PIK3CA mutations or amplification. Studying models of therapeutic resistance, we have observed that SCC cells that become refractory to PI3Kα inhibition maintain PI3K-independent activation of the mammalian target of rapamycin (mTOR). This persistent mTOR activation is mediated by the tyrosine kinase receptor AXL. AXL is overexpressed in resistant tumors from both laboratory models and patients treated with the PI3Kα inhibitor BYL719. AXL dimerizes with and phosphorylates epidermal growth factor receptor (EGFR), resulting in activation of phospholipase Cγ (PLCγ)-protein kinase C (PKC), which, in turn, activates mTOR. Combined treatment with PI3Kα and either EGFR, AXL, or PKC inhibitors reverts this resistance.
[Mh] MeSH terms primary: Carcinoma, Squamous Cell/metabolism
Esophageal Neoplasms/metabolism
Head and Neck Neoplasms/metabolism
Proto-Oncogene Proteins/physiology
Receptor Protein-Tyrosine Kinases/physiology
[Mh] MeSH terms secundary: Animals
Antibodies, Monoclonal, Humanized/pharmacology
Cell Line, Tumor
Drug Resistance, Neoplasm
Humans
Mice
Phosphatidylinositol 3-Kinases/antagonists & inhibitors
Phosphatidylinositol 3-Kinases/genetics
Phosphatidylinositol 3-Kinases/metabolism
Protein Kinase C/metabolism
Protein Kinase Inhibitors/pharmacology
Proto-Oncogene Proteins/genetics
Proto-Oncogene Proteins/metabolism
Receptor Protein-Tyrosine Kinases/genetics
Receptor Protein-Tyrosine Kinases/metabolism
Signal Transduction
TOR Serine-Threonine Kinases/metabolism
Thiazoles/pharmacology
Xenograft Model Antitumor Assays
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Antibodies, Monoclonal, Humanized); 0 (NVP-BYL719); 0 (Protein Kinase Inhibitors); 0 (Proto-Oncogene Proteins); 0 (Thiazoles); EC 2.7.1.- (Phosphatidylinositol 3-Kinases); EC 2.7.1.1 (MTOR protein, human); EC 2.7.1.1 (TOR Serine-Threonine Kinases); EC 2.7.1.137 (PIK3CA protein, human); EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases); EC 2.7.10.1 (axl receptor tyrosine kinase); EC 2.7.11.13 (Protein Kinase C); PQX0D8J21J (cetuximab)
[Em] Entry month:1506
[Cu] Class update date: 150718
[Lr] Last revision date:150718
[Js] Journal subset:IM
[Da] Date of entry for processing:150415
[St] Status:MEDLINE

  10 / 349463 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 25107914
[Au] Autor:Egloff AM; Lee JW; Langer CJ; Quon H; Vaezi A; Grandis JR; Seethala RR; Wang L; Shin DM; Argiris A; Yang D; Mehra R; Ridge JA; Patel UA; Burtness BA; Forastiere AA
[Ad] Address:University of Pittsburgh, Pittsburgh, Pennsylvania. egloffam@upmc.edu....
[Ti] Title:Phase II study of cetuximab in combination with cisplatin and radiation in unresectable, locally advanced head and neck squamous cell carcinoma: Eastern cooperative oncology group trial E3303.
[So] Source:Clin Cancer Res;20(19):5041-51, 2014 Oct 1.
[Is] ISSN:1078-0432
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:PURPOSE: Treatment with cisplatin or cetuximab combined with radiotherapy each yield superior survival in locally advanced squamous cell head and neck cancer (LA-SCCHN) compared with radiotherapy alone. Eastern Cooperative Oncology Group Trial E3303 evaluated the triple combination. EXPERIMENTAL DESIGN: Patients with stage IV unresectable LA-SCCHN received a loading dose of cetuximab (400 mg/m(2)) followed by 250 mg/m(2)/week and cisplatin 75 mg/m(2) q 3 weeks 3 cycles concurrent with standard fractionated radiotherapy. In the absence of disease progression or unacceptable toxicity, patients continued maintenance cetuximab for 6 to 12 months. Primary endpoint was 2-year progression-free survival (PFS). Patient tumor and blood correlates, including tumor human papillomavirus (HPV) status, were evaluated for association with survival. RESULTS: A total of 69 patients were enrolled; 60 proved eligible and received protocol treatment. Oropharyngeal primaries constituted the majority (66.7%), stage T4 48.3% and N2-3 91.7%. Median radiotherapy dose delivered was 70 Gy, 71.6% received all three cycles of cisplatin, and 74.6% received maintenance cetuximab. Median PFS was 19.4 months, 2-year PFS 47% [95% confidence interval (CI), 33%-61%]. Two-year overall survival (OS) was 66% (95% CI, 53%-77%); median OS was not reached. Response rate was 66.7%. Most common grade ≥3 toxicities included mucositis (55%), dysphagia (46%), and neutropenia (26%); one attributable grade 5 toxicity occurred. Only tumor HPV status was significantly associated with survival. HPV was evaluable in 29 tumors; 10 (all oropharyngeal) were HPV positive. HPV(+) patients had significantly longer OS and PFS (P = 0.004 and P = 0.036, respectively). CONCLUSIONS: Concurrent cetuximab, cisplatin, and radiotherapy were well tolerated and yielded promising 2-year PFS and OS in LA-SCCHN with improved survival for patients with HPV(+) tumors.
[Mh] MeSH terms primary: Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Carcinoma, Squamous Cell/drug therapy
Carcinoma, Squamous Cell/radiotherapy
Head and Neck Neoplasms/drug therapy
Head and Neck Neoplasms/radiotherapy
[Mh] MeSH terms secundary: Adult
Aged
Antibodies, Monoclonal, Humanized/administration & dosage
Carcinoma, Squamous Cell/etiology
Carcinoma, Squamous Cell/mortality
Carcinoma, Squamous Cell/pathology
Cisplatin/administration & dosage
Disease Progression
Female
Head and Neck Neoplasms/etiology
Head and Neck Neoplasms/mortality
Head and Neck Neoplasms/pathology
Humans
Male
Middle Aged
Neoplasm Metastasis
Neoplasm Staging
Radiotherapy
Risk Factors
Treatment Outcome
[Pt] Publication type:CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Name of substance:0 (Antibodies, Monoclonal, Humanized); PQX0D8J21J (cetuximab); Q20Q21Q62J (Cisplatin)
[Em] Entry month:1506
[Cu] Class update date: 150718
[Lr] Last revision date:150718
[Js] Journal subset:IM
[Da] Date of entry for processing:141002
[St] Status:MEDLINE
[do] DOI:10.1158/1078-0432.CCR-14-0051


page 1 of 34947 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information